Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies
Version of Record online: 7 OCT 2010
© 2010 The Authors. Journal of Neurochemistry © 2010 International Society for Neurochemistry
Journal of Neurochemistry
Special Issue: Introducing Preclinical Systematic Reviews
Volume 115, Issue 4, pages 806–813, November 2010
How to Cite
Gibson, C. L. and Murphy, S. P. (2010), Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. Journal of Neurochemistry, 115: 806–813. doi: 10.1111/j.1471-4159.2010.06993.x
- Issue online: 21 OCT 2010
- Version of Record online: 7 OCT 2010
- Accepted manuscript online: 10 SEP 2010 06:42PM EST
- Received July 19, 2010; revised manuscript received September 1, 2010; accepted September 2, 2010.
- CNS injury;
- systematic review;
- histone deacetylase;
J. Neurochem. (2010) 115, 806–813.
Drugs that inhibit histone deacetylase (HDAC) activities have enormous potential as neuroprotective agents. We performed a systematic review of controlled animal studies that administered known inhibitors of the zinc-dependent HDACs before and/or after acute cerebral injury and assessed anatomic/functional outcomes. Relevant studies were found by searching PubMed, Embase and Web of Science. From more than 100 identified publications, those data meeting specific criteria were analyzed using the Cochrane Review Manager software. A beneficial effect of administering HDAC inhibitors was seen in studies involving cerebral ischemia or non-ischemic models of acute cerebral injury. Specific studies assessed efficacy when drug was administered up to 14 days prior to, and 14 days following, the onset of cerebral injury. This systematic review provides objective evidence of a neuroprotective role for drugs that inhibit HDACs and highlights particular areas that require further experimental investigation.